(Q44950915)

7 December 2017

title

Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma (English)

1 reference

7 December 2017

1

1 reference

7 December 2017

9

1 reference

7 December 2017

P Cernohous

2

1 reference

7 December 2017

A Engert

3

1 reference

7 December 2017

S Le Gouill

4

1 reference

7 December 2017

D Macdonald

5

1 reference

7 December 2017

C Machida

6

1 reference

7 December 2017

H Myint

7

1 reference

7 December 2017

A Saleh

8

1 reference

7 December 2017

M Wilhelm

10

1 reference

7 December 2017

R van der Jagt

11

1 reference

7 December 2017

publication date

14 August 2013

1 reference

7 December 2017

1 reference

7 December 2017

volume

24

1 reference

7 December 2017

issue

10

1 reference

7 December 2017

page(s)

2618-2623

1 reference

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT289

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT289

Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT289

The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT289

A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT289

Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT289

Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognos

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT289

Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT289

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDT289

1 reference

7 December 2017

1 reference